Artificial Intelligence in Magnetic Resonance Imaging-based Prostate Cancer Diagnosis: Where Do We Stand in 2021?


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
03 2022
Historique:
received: 29 01 2021
revised: 25 02 2021
accepted: 14 03 2021
pubmed: 29 3 2021
medline: 9 6 2022
entrez: 28 3 2021
Statut: ppublish

Résumé

Men suspected of harboring prostate cancer (PCa) increasingly undergo multiparametric magnetic resonance imaging (mpMRI) and mpMRI-guided biopsy. The potential of mpMRI coupled to artificial intelligence (AI) methods to detect and classify PCa before decision-making requires investigation. To review the literature for studies addressing the diagnostic performance of combined mpMRI and AI approaches to detect and classify PCa, and to provide selection criteria for relevant articles having clinical significance. We performed a nonsystematic search of the English language literature using the PubMed-MEDLINE database up to October 30, 2020. We included all original studies addressing the diagnostic accuracy of mpMRI and AI to detect and classify PCa with histopathological analysis as a reference standard. Eleven studies assessed AI and mpMRI approaches for PCa detection and classification based on a ground truth that referred to the entire prostate either with radical prostatectomy specimens (RPS) or relocalization of positive systematic and/or targeted biopsy. Seven studies retrospectively annotated cancerous lesions onto mpMRI identified in whole-mount sections from RPS, three studies used a backward projection of histological prostate biopsy information, and one study used a combined cohort of both approaches. All studies cross-validated their data sets; only four used a test set and one a multisite validation scheme. Performance metrics for lesion detection ranged from 87.9% to 92% at a threshold specificity of 50%. The lesion classification accuracy of the algorithms was comparable to that of the Prostate Imaging-Reporting and Data System. For an algorithm to be implemented into radiological workflows and to be clinically applicable, it must be trained with a ground truth labeling that reflects histopathological information for the entire prostate and it must be externally validated. Lesion detection and classification performance metrics are promising but require prospective implementation and external validation for clinical significance. We reviewed the literature for studies on prostate cancer detection and classification using magnetic resonance imaging (MRI) and artificial intelligence algorithms. The main application is in supporting radiologists in interpreting MRI scans and improving the diagnostic performance, so that fewer unnecessary biopsies are carried out.

Identifiants

pubmed: 33773964
pii: S2405-4569(21)00099-7
doi: 10.1016/j.euf.2021.03.020
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-417

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Rodrigo Suarez-Ibarrola (R)

Department of Urology, Faculty of Medicine, University of Freiburg Medical Centre, Freiburg, Germany. Electronic address: rodrigo.suarez@uniklinik-freiburg.de.

August Sigle (A)

Department of Urology, Faculty of Medicine, University of Freiburg Medical Centre, Freiburg, Germany.

Martin Eklund (M)

Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

Daniel Eberli (D)

Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Arkadiusz Miernik (A)

Department of Urology, Faculty of Medicine, University of Freiburg Medical Centre, Freiburg, Germany.

Matthias Benndorf (M)

Department of Radiology, Faculty of Medicine, University of Freiburg Medical Centre, Freiburg, Germany.

Fabian Bamberg (F)

Department of Radiology, Faculty of Medicine, University of Freiburg Medical Centre, Freiburg, Germany.

Christian Gratzke (C)

Department of Urology, Faculty of Medicine, University of Freiburg Medical Centre, Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH